Faron Pharmaceuticals Oy (FARN) News Today GBX 190 +5.00 (+2.70%) As of 09/12/2025 10:33 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock FARN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Faron Pharmaceuticals Oy’s Bexmarilimab Shows Promise in HR-MDS Trials with FDA Support, Reinforcing Buy RatingSeptember 12 at 12:11 PM | tipranks.comFaron Pharmaceuticals Oy (LON:FARN) Shares Pass Below Fifty Day Moving Average - Here's What HappenedSeptember 11 at 5:09 AM | marketbeat.comFaron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025August 28, 2025 | finance.yahoo.comFaron Pharmaceuticals Achieves Key Milestones in H1 2025August 27, 2025 | msn.comFaron Pharmaceuticals Ltd: Notice of Half-Year Financial ResultsAugust 19, 2025 | finance.yahoo.comFaron Pharmaceuticals Advances Bexmarilimab in HR-MDS Treatment Following FDA GuidanceAugust 18, 2025 | msn.comInside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (frontline) HR-MDS after Positive Meeting with the FDAAugust 18, 2025 | finance.yahoo.comTop UK Growth Companies With Insider Ownership In August 2025August 15, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Stock Crosses Below 50 Day Moving Average - Here's WhyAugust 9, 2025 | marketbeat.comFaron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche BondsAugust 8, 2025 | finance.yahoo.comFaron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent GrantedAugust 8, 2025 | finance.yahoo.comFaron Pharmaceuticals: Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent GrantedAugust 8, 2025 | finanznachrichten.deFaron Pharmaceuticals reports higher remission rates in cancer trialAugust 6, 2025 | investing.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Down 5.3% - Should You Sell?August 1, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Pass Above 50 Day Moving Average - What's Next?July 10, 2025 | marketbeat.comFaron Pharmaceuticals: Faron Announces Acceptance of Two Studies Involving Bexmarilimab, One of Them as an Oral Presentation, at the 19th International Congress of Immunology 2025July 9, 2025 | finanznachrichten.deFaron Pharmaceuticals Oy (FARN) - Investing.com UKJuly 2, 2025 | uk.investing.comFaron Pharmaceuticals Oy (LON:FARN) Share Price Crosses Below 50-Day Moving Average - Here's WhyJune 28, 2025 | marketbeat.comMarkku Jalkanen Sells 600,000 Shares of Faron Pharmaceuticals Oy (LON:FARN) StockJune 6, 2025 | insidertrades.comInsider Selling: Faron Pharmaceuticals Oy (LON:FARN) Insider Sells 600,000 Shares of StockJune 5, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Down 9% - Time to Sell?June 4, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Sets New 1-Year High - Here's What HappenedMay 31, 2025 | marketbeat.comFaron Pharmaceuticals: Faron's Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid MalignanciesMay 28, 2025 | finanznachrichten.deFaron’s Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid MalignanciesMay 28, 2025 | finance.yahoo.comFaron Appoints Ralph Hughes as Chief Business Officer (CBO)May 21, 2025 | finance.yahoo.comFaron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 CongressMay 15, 2025 | finance.yahoo.comFaron Pharmaceuticals Ltd: Grant of OptionsMay 14, 2025 | finance.yahoo.comFaron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary SessionMay 12, 2025 | finance.yahoo.com3 UK Growth Companies With High Insider Ownership And 56% Earnings GrowthMay 9, 2025 | finance.yahoo.comHigh Growth Tech Stocks to Watch in May 2025May 8, 2025 | finance.yahoo.comFaron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025April 24, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Down 14% - Time to Sell?April 18, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Hits New 1-Year High - Here's What HappenedApril 16, 2025 | marketbeat.comInside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic SyndromeApril 15, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Above Fifty Day Moving Average - Should You Sell?March 30, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Above Fifty Day Moving Average - Should You Sell?March 21, 2025 | marketbeat.comShareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be ElectedMarch 20, 2025 | finance.yahoo.comFaron Pharmaceuticals Oy (LON:FARN) Shares Pass Below 50 Day Moving Average - Here's WhyMarch 13, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?March 5, 2025 | marketbeat.comFaron Pharmaceuticals Oy: Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDSMarch 3, 2025 | finanznachrichten.deFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 50 Day Moving Average - Time to Sell?February 25, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Shares Cross Below 200 Day Moving Average - Here's What HappenedFebruary 15, 2025 | marketbeat.comFaron Pharmaceuticals Oy (LON:FARN) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?February 15, 2025 | marketbeat.comFaron Pharmaceuticals Regulatory NewsFebruary 9, 2025 | lse.co.ukFaron Pharmaceuticals Oy (LON:FARN) Stock Crosses Below Fifty Day Moving Average - What's Next?February 7, 2025 | marketbeat.comFaron Pharmaceuticals seeks EUR 10 million in private placementFebruary 5, 2025 | msn.comFaron completes enrollment for BEXMAB Phase II MDS studyJanuary 31, 2025 | msn.comFaron Pharmaceuticals Oy (LON:FARN) Share Price Passes Below 50 Day Moving Average - Here's WhyDecember 27, 2024 | marketbeat.comFaron Pharmaceuticals Reports Promising BEXMAB Trial ResultsDecember 11, 2024 | markets.businessinsider.comFaron Pharma CEO talks about MHRA fast-track and phase III plans - ICYMIDecember 7, 2024 | uk.investing.com Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FARN Media Mentions By Week FARN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FARN News Sentiment▼0.930.93▲Average Medical News Sentiment FARN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FARN Articles This Week▼21▲FARN Articles Average Week Get the Latest News and Ratings for FARN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Faron Pharmaceuticals Oy and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Oxford Biomedica News PureTech Health News Avacta Group News 4basebio News Bioventix News Scancell News hVIVO News ImmuPharma News Hemogenyx Pharmaceuticals News SkinBioTherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:FARN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
